Log in
NASDAQ:CBAY

CymaBay Therapeutics Stock Forecast, Price & News

$6.23
-0.31 (-4.74 %)
(As of 09/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$6.17
Now: $6.23
$6.86
50-Day Range
$5.25
MA: $6.20
$6.92
52-Week Range
$1.21
Now: $6.23
$7.09
Volume1.20 million shs
Average Volume1.49 million shs
Market Capitalization$429.18 million
P/E RatioN/A
Dividend YieldN/A
Beta1.72
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, a selective orally-active G protein-coupled receptor agonist that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion for the treatment of gut/liver disease. Its preclinical stage product candidate is CB-001, a G protein-coupled receptor for omega-3 fatty acids, such as docosahexaenoic acid for the treatment of gut/liver disease. It has development and licensing agreement with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type II diabetes and other disorders; and a license agreement with DiaTex, Inc. to develop and commercialize therapeutic products comrprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
Read More
CymaBay Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.70 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CBAY
CUSIPN/A
Phone510-293-8800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10 million
Book Value$2.71 per share

Profitability

Net Income$-102,810,000.00

Miscellaneous

Employees43
Market Cap$429.18 million
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$6.23
-0.31 (-4.74 %)
(As of 09/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CBAY News and Ratings via Email

Sign-up to receive the latest news and ratings for CBAY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











CymaBay Therapeutics (NASDAQ:CBAY) Frequently Asked Questions

How has CymaBay Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

CymaBay Therapeutics' stock was trading at $1.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CBAY shares have increased by 304.5% and is now trading at $6.23.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of CymaBay Therapeutics?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last year. There are currently 1 hold rating, 10 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for CymaBay Therapeutics
.

When is CymaBay Therapeutics' next earnings date?

CymaBay Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for CymaBay Therapeutics
.

How were CymaBay Therapeutics' earnings last quarter?

CymaBay Therapeutics Inc (NASDAQ:CBAY) posted its earnings results on Monday, August, 10th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.07.
View CymaBay Therapeutics' earnings history
.

What price target have analysts set for CBAY?

12 Wall Street analysts have issued twelve-month price targets for CymaBay Therapeutics' stock. Their forecasts range from $6.00 to $20.00. On average, they anticipate CymaBay Therapeutics' stock price to reach $12.82 in the next year. This suggests a possible upside of 105.7% from the stock's current price.
View analysts' price targets for CymaBay Therapeutics
.

Are investors shorting CymaBay Therapeutics?

CymaBay Therapeutics saw a decrease in short interest during the month of August. As of August 14th, there was short interest totaling 6,930,000 shares, a decrease of 29.4% from the July 30th total of 9,810,000 shares. Based on an average daily volume of 3,640,000 shares, the days-to-cover ratio is currently 1.9 days. Approximately 13.6% of the company's shares are sold short.
View CymaBay Therapeutics' Short Interest
.

Who are some of CymaBay Therapeutics' key competitors?

What other stocks do shareholders of CymaBay Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CymaBay Therapeutics investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Advanced Micro Devices (AMD), Opko Health (OPK), Novavax (NVAX), Pfizer (PFE), Alibaba Group (BABA), Corbus Pharmaceuticals (CRBP), Energy Transfer LP Unit (ET) and TG Therapeutics (TGTX).

Who are CymaBay Therapeutics' key executives?

CymaBay Therapeutics' management team includes the following people:
  • Mr. Sujal A. Shah, Pres, CEO & Director (Age 46)
  • Mr. Daniel Menold, VP of Fin. (Age 49)
  • Dr. Charles A. McWherter, Sr. VP & Chief Scientific Officer (Age 64)
  • Mr. Paul T. Quinlan, Gen. Counsel & Corp. Sec. (Age 56)
  • Dr. Pol F. Boudes, Chief Medical Officer (Age 62)

What is CymaBay Therapeutics' stock symbol?

CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY."

Who are CymaBay Therapeutics' major shareholders?

CymaBay Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Engine Capital Management LP (2.56%), Ikarian Capital LLC (2.22%), Point72 Asset Management L.P. (0.84%), Bridgeway Capital Management Inc. (0.72%), Charles Schwab Investment Management Inc. (0.63%) and UBS Group AG (0.55%). Company insiders that own CymaBay Therapeutics stock include Carl Goldfischer, Kurt Von Emster and Sujal Shah.
View institutional ownership trends for CymaBay Therapeutics
.

Which major investors are selling CymaBay Therapeutics stock?

CBAY stock was sold by a variety of institutional investors in the last quarter, including Engine Capital Management LP, Ikarian Capital LLC, Nuveen Asset Management LLC, Bank of America Corp DE, and Bank of New York Mellon Corp.
View insider buying and selling activity for CymaBay Therapeutics
.

Which major investors are buying CymaBay Therapeutics stock?

CBAY stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Bridgeway Capital Management Inc., Jacobs Levy Equity Management Inc., Hudson Bay Capital Management LP, ClariVest Asset Management LLC, Algert Global LLC, Charles Schwab Investment Management Inc., and WINTON GROUP Ltd.
View insider buying and selling activity for CymaBay Therapeutics
.

How do I buy shares of CymaBay Therapeutics?

Shares of CBAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CymaBay Therapeutics' stock price today?

One share of CBAY stock can currently be purchased for approximately $6.23.

How big of a company is CymaBay Therapeutics?

CymaBay Therapeutics has a market capitalization of $429.17 million and generates $10 million in revenue each year. The biopharmaceutical company earns $-102,810,000.00 in net income (profit) each year or ($1.46) on an earnings per share basis. CymaBay Therapeutics employs 43 workers across the globe.

What is CymaBay Therapeutics' official website?

The official website for CymaBay Therapeutics is www.cymabay.com.

How can I contact CymaBay Therapeutics?

CymaBay Therapeutics' mailing address is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at 510-293-8800 or via email at [email protected]

This page was last updated on 9/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.